1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. SUDEEP PHARMA LTD.
Sudeep Pharma Ltd.
NSE: SUDEEPPHRM | BSE: 544619
US FDA InspectionsANDA Approvals
Ask AI about Sudeep Pharma
1217.5047.80(4.09%)
277.8K
NSE+BSE Volume

NSE 17 Nov, 2026 3:31 PM

Portfolio

Alert

My Notes

Sudeep Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Sudeep Pharma quarterly results: revenue, profit, and P&L – 13 quarter history

  • POSITIVE

    Quarterly Revenue Sudeep Pharma Sep-2026 Quarterly Revenue is Rs 148 Cr which is growth of 46.9% YoY.

  • POSITIVE

    Quarterly Net Profit Sudeep Pharma Sep-2026 Quarterly Net Profit is Rs 42 Cr which is growth of 42.4% YoY.

Sudeep Pharma Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
⌄
147.9115.589.899.7100.786.810885.8
Operating Exp.
85.866.551.360.75749.859.457
Operating Profit
51.639.228.929.630.930.445.526.5
Operating Profit Margin %
37.56%37.09%36.03%32.80%35.14%37.91%43.36%31.70%
Depr.
3.11.81.81.81.81.81.71.5
Interest
2.31.820.621.41.61.3
Profit Before Tax
56.845.434.736.639.933.845.326
Tax
14.411.699.810.28.612.25.3
Net Profit
42.333.825.826.929.725.233.120.6
EPS Adj. latest
3.832.32.42.62.22.91.8
Net profit TTM
128.8116.2107.6115108.7---
Basic EPS TTM
11.410.39.510.211.2---
Earnings Transcripts
   
Results PDF
   
Result Notes
   
*All financials are in INR Cr and price data in INR

Sudeep Pharma competitor comparison and performance snapshot within industry

Sudeep Pharma revenue mix: sales, profit, and capital employed breakups by segment

Sudeep Pharma annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

  • POSITIVE

    Annual Revenue Sudeep Pharma Mar-2026 Annual Revenue is Rs 377 Cr which is growth of 3.3% YoY.

  • POSITIVE

    Annual Net Profit Sudeep Pharma Mar-2026 Annual Net Profit is Rs 108 Cr which is growth of 12.4% YoY.

Sudeep Pharma Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsTTMMar '26Mar '25Mar '24Mar '23
-3.2%
452.9377365.1352415.2
Operating Exp. Ann.
-11.5%
264.2218.7224.8211.5315.7
Operating Profit Ann.
10.7%
149.3119.8132132.288.3
OPM Ann. %
14.3%
 31.77%36.14%37.57%21.26%
⌄
-10.6%
 231.9235.7219.7324.4
EBITDA Ann.
16.8%
 158.3140.3140.499.4
EBITDA Ann. margin %
20.6%
 41.98%38.44%39.90%23.95%
Interest Ann.
17.1%
6.76.14.833.8
Depr.
13.9%
8.57.16.15.24.8
PBT Ann.
16.9%
173.5145.1129.4132.390.8
Tax Ann.
16.7%
44.737.533.734.223.6
17%
 107.695.898.167.2
Net Profit Ann.
17%
128.8107.695.898.167.2
NPM Ann. %
24.1%
 31.78%26.84%28.53%16.62%
EPS Adj. latest Ann.
16.6%
 9.58.58.76
Result Notes
    
Annual Reports
    
*All financials are in INR Cr and price data in INR
Total Rev. Ann.
1Y CHG
3.3%
2Y CAGR
3.5%
3Y CAGR
-3.2%
Net Profit Ann.
1Y CHG
12.3%
2Y CAGR
4.7%
3Y CAGR
17%
Operating Exp. Ann.
1Y CHG
-2.7%
2Y CAGR
1.7%
3Y CAGR
-11.5%

Sudeep Pharma balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

  • POSITIVE

    Total Shareholders Fund Sudeep Pharma Mar-2026 Total Shareholders Fund is Rs 786 Cr which is growth of 82.7% YoY.

  • POSITIVE

    Total Assets Sudeep Pharma Mar-2026 Total Assets is Rs 974 Cr which is growth of 61.2% YoY.

Sudeep Pharma Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsMar '26Mar '25Mar '24Mar '23
⌄
49.1%
786430.1334.6236.9
Minority Interest Liability Ann.
-
----
⌄
40.5%
42.740.911.515.4
-3.9%
145.1130.8104.5163.7
Total Capital Plus Liabilities Ann.
32.8%
973.8604.1450.6416
⌄
31.6%
263193139.4115.4
⌄
42%
515.8291.1219.9180.2
24.8%
458313230.8235.9
Total Assets Ann.
32.8%
973.8604.1450.6416
Contingent Liabilities plus Commitments Ann.
-20.3%
7.2127.419.814.2
Bonus Equity Share Capital Ann.
-
0.80.8
Non Current Investments Unquoted Book Value Ann.
26.9%
32.131.428.615.7
Current Investments Unquoted Book Value Ann.
-
*All financials are in INR Cr and price data in INR
Total Assets Ann.
1Y CHG
61.2%
2Y CAGR
47%
3Y CAGR
32.8%
Total Current Liabilities Ann.
1Y CHG
10.9%
2Y CAGR
17.8%
3Y CAGR
-3.9%
Total ShareHolders Funds Ann.
1Y CHG
82.7%
2Y CAGR
53.3%
3Y CAGR
49.1%

Sudeep Pharma ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

  • POSITIVE

    Book Value Per Share Sudeep Pharma Mar-2026 Book Value Per Share is 70 Rs which is growth of 58.1% YoY.

  • POSITIVE

    ROE Sudeep Pharma Mar-2026 ROE is 14% which is growth of 8.7% YoY.

Sudeep Pharma Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsMar '26Mar '25Mar '24Mar '23
BVSH Ann.
-65.4%
69.6442,374.61,681.1
RoA Ann. %
-11.9%
11.04%15.84%21.76%16.14%
ROE Ann. %
-21.6%
13.68%22.37%29.31%28.35%
ROCE Ann. %
-21.3%
18.24%28.35%39.08%37.49%
⌄
-
    
⌄
-
    
⌄
-
    
Total Debt to Total Equity Ann.
-12.6%
0.20.30.20.3
*All financials are in INR Cr and price data in INR
ROE Ann. %
1Y CHG
-38.8%
2Y CAGR
-31.7%
3Y CAGR
-21.6%
RoA Ann. %
1Y CHG
-30.3%
2Y CAGR
-28.8%
3Y CAGR
-11.9%
Current Ratio Ann.
1Y CHG
33.3%
2Y CAGR
20.6%
3Y CAGR
31.7%

Sudeep Pharma cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

  • POSITIVE

    Cash From Operating Activity Sudeep Pharma Mar-2026 Cash From Operating Activity is Rs 96 Cr which is growth of 62.3% YoY.

  • NEGATIVE

    Net Cash Flow Sudeep Pharma Mar-2026 Net Cash Flow is Rs -28 Cr which is growth of -229.5% YoY.

Sudeep Pharma Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsMar '26Mar '25Mar '24Mar '23
31.4%
9659.259.142.3
Cash from Investing Act. Ann.
-
-366.7-91.6-40.7-40.7
Cash from Financing Act. Ann.
-
242.554.2-16.1-10.1
-
-28.221.82.2-8.5
*All financials are in INR Cr and price data in INR
Cash from Operating Act. Ann.
1Y CHG
62.2%
2Y CAGR
27.5%
3Y CAGR
31.4%
Cash from Financing Act. Ann.
1Y CHG
347.4%

Sudeep Pharma investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access